Fat-Derived stem cells injected into spine to fight progressive MS
NCT ID NCT06592703
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether repeated injections of stem cells from donated fat tissue are safe for people with primary progressive multiple sclerosis (MS). Ten participants will receive the cells directly into the spinal canal. The main goal is to check for serious side effects, but researchers will also watch for any signs that the treatment might slow disability progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor fat-derived stem cells (mesenchymal stromal cells)
What this could lead to
If safe and effective, this could point toward a new way to slow or stop worsening disability in primary progressive multiple sclerosis.
What could go wrong
This is a very early, small phase 1 trial focused on safety, not proof of benefit. The treatment may not work, and there are risks from the injections and the cells themselves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Henri Mondor
ACTIVE_NOT_RECRUITINGCréteil, France
-
CHU Rennes
RECRUITINGRennes, France
Contact
Contact